Table 1.
Summary of the clinical data of patients with and without CAD
| Variable | CAD (n = 28) | Non-CAD (n = 17) | p-value |
|---|---|---|---|
| • Patient’s characteristics | |||
| Male gender, n (%) | 25 (89.3) | 11 (64.7) | 0.0626 |
| Age, years (mean ± SD) | 71.04 ± 10.54 | 65.94 ± 13.33 | 0.1906 |
| • Associated diseases/risk factors | |||
| Smoking, n (%) | 2 (7.1) | 3 (17.7) | 0.3504 |
| Hypertension, n (%) | 18 (64.3) | 10 (58.8) | 0.7591 |
| Diabetes, n (%) | 11 (39.3) | 2 (11.8) | 0.0881 |
| Chronic renal failure, n (%) | 2 (7.1) | 0 (0.0) | 0.5192 |
| COPD, n (%) | 3 (10.7) | 0 (0.0) | 0.2788 |
| BMI (mean ± SD) | 29.61 ± 5.76 | 27.60 ± 5.57 | 0.4311 |
| Dental procedure-related variables | |||
| Number of extracted teeth (mean ± SD) | 2.18 ± 1.36 | 2.12 ± 1.41 | 0.8876 |
| Flap opened, n (%) | 12 (42.8) | 6 (35.3) | 0.7566 |
| Bone removal, n (%) | 7 (25.0) | 4 (23.5) | 1.0000 |
| Number of LA carpules (mean ± SD) | 2.29 ± 0.88 | 2.21 ± 0.83 | 0.7612 |
| Oral sedation (20 mg of diazepam), n (%) | 10 (35.7) | 4 (23.5) | 0.5134 |
| Preoperative GTN, n (%) | 1 (3.6) | 0 (0.0) | 1.0000 |
| Antibiotic cover, n (%) | 1 (3.6) | 5 (29.4) | 0.0228 |
| • Medications | |||
| Single antiplatelets, n (%) | 13 (46.4) | 5 (29.4) | 0.3523 |
| Dual antiplatelets, n (%) | 3 (10.7) | 0 (0.0) | 0.2788 |
| Beta-blockers, n (%) | 18 (64.3) | 6 (35.3) | 0.0727 |
| Statins, n (%) | 19 (67.9) | 7 (41.2) | 0.1206 |
| Ezetimibe, n (%) | 5 (17.6) | 0 (0.0) | 0.1401 |
| Warfarin, n (%) | 7 (25.0) | 5 (29.4) | 0.7428 |
| ACE inhibitors, n (%) | 16 (57.1) | 7 (41.2) | 0.3651 |
| Calcium channel blockers, n (%) | 7 (25.0) | 3 (17.7) | 0.7189 |
| Nitrates, n (%) | 4 (14.3) | 0 (0.0) | 0.2812 |
| Cardiac glycosides, n (%) | 4 (14.3) | 0 (0.0) | 0.2812 |
| Proton-pump inhibitors, n (%) | 5 (17.6) | 2 (11.8) | 0.6932 |
| Diuretics, n (%) | 8 (28.6) | 7 (41.2) | 0.5167 |
| Alpha-1 blockers, n (%) | 3 (10.7) | 1 (5.9) | 1.0000 |
| ARBs, n (%) | 1 (3.6) | 2 (11.8) | 0.5571 |
| Oral hypoglycemics, n (%) | 7 (25.0) | 3 (17.7) | 0.7189 |
| Insulin, n (%) | 1 (3.6) | 0 (0.0) | 1.0000 |
| Seretide inhaler, n (%) | 2 (7.1) | 0 (0.0) | 0.5192 |
| Anticholinergics, n (%) | 3 (10.7) | 0 (0.0) | 0.2788 |
| Beta-2 agonists, n (%) | 5 (17.6) | 0 (0.0) | 0.1401 |
| Antiepileptics, n (%) | 2 (7.1) | 1 (5.9) | 1.0000 |
| Antidepressants, n (%) | 4 (14.3) | 1 (5.9) | 0.6353 |
ACE inhibitors angiotensin-converting enzyme inhibitors, ARBS angiotensin receptor blockers, BMI body mass index, COPD chronic obstructive pulmonary disease, GTN glyceryl trinitrate, LA local anesthetic